pdufa.bio
CalendarReadoutsDevicesDecisionsApprovals/yrTrial oddsLearnResearchMethodology
Home › Readouts › March 2027

March 2027 clinical-trial readouts

trial-readout estimates for March 2027, each row linked to its primary source. Readout dates are estimated primary-completion windows from ClinicalTrials.gov and shift.
← February 2027April 2027 →
45 readouts
ADCT · Mar 2027 (est.)
Loncastuximab Tesirine — Relapsed or Refractory Large B-cell Lymphoma
SPTX · Mar 2027 (est.)
SPT-300 — Major Depressive Disorder (MDD)
MNKD · Mar 2027 (est.)
Afrezza — Type 1 Diabetes Mellitus
NUVB · Mar 2027 (est.)
safusidenib — Advanced Solid Tumor
OCGN · Mar 2027 (est.)
OCU410ST — Retinitis Pigmentosa
OCUL · Mar 2027 (est.)
Otx-Tki — Non-Proliferative Diabetic Retinopathy
ONC · Mar 2027 (est.)
Zanubrutinib — Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
PCVX · Mar 2027 (est.)
31-valent pneumococcal conjugate vaccine — Pneumococcal Vaccines
PEPG · Mar 2027 (est.)
PGN-EDODM1 — Myotonic Dystrophy 1
PMVP · Mar 2027 (est.)
rezatapopt — TP53 Y220C Mutation
PSTV · Mar 2027 (est.)
Rhenium Liposome Treatment — Ependymoma
STOK · Mar 2027 (est.)
zorevunersen — Dravet Syndrome
SXTP · Mar 2027 (est.)
Tafenoquine — Babesiosis
URGN · Mar 2027 (est.)
UGN-104 — Upper Urinary Tract Urothelial Carcinoma
VSTM · Mar 2027 (est.)
avutometinib — Mesonephric Gynecologic Cancer
AGIO · Mar 2027 (est.)
Mitapivat — Chondrosarcoma
ALC · Mar 2027 (est.)
Vehicle — Ocular Hyperemia
ALGS · Mar 2027 (est.)
ALG-000184 — Chronic Hepatitis B Infection
ALLR · Mar 2027 (est.)
2X-121 — Advanced Ovarian Cancer
AURA · Mar 2027 (est.)
Bel-sar — Non-muscle-invasive Bladder Cancer
IPHA · Mar 2027 (est.)
Monalizumab — Metastatic Cancer
MDGL · Mar 2027 (est.)
Resmetirom — Non-Alcoholic Fatty Liver Disease
IONS · Mar 2027 (est.)
Olezarsen — Severe Hypertriglyceridemia
FDMT · Mar 2027 (est.)
4D-150 IVT — Neovascular (Wet) Age-Related Macular Degeneration
BMRN · Mar 2027 (est.)
Vosoritide — Noonan Syndrome
BPTH · Mar 2027 (est.)
BP1001 in combination with Ventoclax plus decitabine — Acute Myeloid Leukemia, in Relapse
CGEN · Mar 2027 (est.)
COM701 — Ovarian Cancer
CLDX · Mar 2027 (est.)
Barzolvolimab — Mild to Moderate Asthma
COGT · Mar 2027 (est.)
CGT9486 — Intrahepatic Cholangiocarcinoma (Icc)
DNLI · Mar 2027 (est.)
BIIB122 — Parkinson Disease
SNDX · Mar 2027 (est.)
Revumenib — Acute Myeloid Leukemia
FBRX · Mar 2027 (est.)
FB102 — Alopecia Areata
TSHA · Mar 2027 (est.)
TSHA-101 — Infantile GM2 Gangliosidosis (Disorder)
TVTX · Mar 2027 (est.)
Pegtibatinase — Focal Segmental Glomerulosclerosis
RYTM · Mar 2027 (est.)
Setmelanotide — Hypothalamic Obesity
ZLAB · Mar 2027 (est.)
ZL-1109 — Thyroid Eye Disease (TED)
UTHR · Mar 2027 (est.)
CDX-1140 — Ovarian Clear Cell Adenocarcinoma
HELP · Mar 2027 (est.)
CYB003 — Major Depressive Disorder (MDD)
BPTH · Mar 2027 (est.)
BP1001 in combination with Ventoclax plus decitabine — Poliomyelitis
GILD · Mar 2027 (est.)
Sacituzumab Govitecan — HER2-negative Breast Cancer
CLDX · Mar 2027 (est.)
Barzolvolimab — Glioblastoma
CGON · Mar 2027 (est.)
Cretostimogene Grenadenorepvec — High-Risk Non-Muscle-Invasive Bladder Cancer
MSLE · Mar 2027 (est.)
SAT-3247 — Duchenne Muscular Dystrophy
TNGX · Mar 2027 (est.)
Abemaciclib — Non Small Cell Lung Cancer
ALT · Mar 2027 (est.)
Pemvidutide — Alcohol Liver Disease
Looking for an approval probability for these? We deliberately don't publish one — here's why, and what we show instead (verified history + base rates).